• andera Partners
  • Am Klopferspitz 19
  • 82152 Planegg / Martinsried
  • Germany
  • moc.srentraparedna@tcatnoc
Managing Director Andera Partners Olivier Litzka

Olivier Litzka
Managing Director Andera Partners

About andera Partners

Created over 20 years ago, Andera Partners is a major European player in private company investments internationally. Its teams manage over €3.2 billion in investments in life sciences, growth and buyout capital, sponsorless transactions and ecological transition.

Headquartered in Paris, with offices in Antwerp and Munich, Andera Partners is wholly owned by its teams, which count about 100 professionals, of which 60 investment professionals. Responsible and committed, the management company regularly also forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming.

Andera’s 15-person life sciences team brings together extensive experience in the life sciences industry, private equity and venture capital. Active since 2000, the team has raised over €1.1 billion through its BioDiscovery family of funds and is currently investing from its new BioDiscovery 6 fund. Since inception, the BioDiscovery funds have invested in more than 75 European and U.S. biotech and medtech companies.

What is your motivation?

We invest in companies developing breakthrough therapeutic products and medical technologies from preclinical stages to commercialisation. We fund the development of innovative medical solutions, which are based on strong scientific hypotheses, supported by robust preclinical or clinical data, and protected by strong intellectual property. We take an active role in our investments, backing talented entrepreneurs to take their innovations to major value inflexion points.  Investing in breakthrough therapeutic innovations has the potential to yield high returns to our investors, in addition to making a real impact on patients’ needs.

”We invest in companies developing breakthrough therapeutic products and medical technologies from preclinical stages to commercialisation.“

Andera Partners